Bordetella Infections, Bordetella Parapertussis Infection, Bordetella Pertussis Infection
Conditions
Brief summary
A three-arm, multi-site clinical evaluation of the ARIES Bordetella Assay for the detection and identification of Bordetella pertussis (B. pertussis) and Bordetella parapertussis (B. parapertussis) nucleic acids in prospectively collected, de-identified, left-over clinical specimens; banked, pre-selected clinical specimens; and contrived specimens.
Detailed description
The ARIES Bordetella Assay is a real-time polymerase chain reaction (PCR) based qualitative in vitro diagnostic test for the direct detection and identification of Bordetella pertussis (B. pertussis) and Bordetella parapertussis (B. parapertussis) nucleic acid in nasopharyngeal swabs (NPS) specimens obtained from individuals suspected of having a respiratory tract infection attributable to B. pertussis or B. parapertussis. Clinical nasopharyngeal swab specimens collected using nasopharyngeal swab in transport media will be processed according to the routine procedure followed at the clinical collection site and as ordered by the referring physician. The leftover specimen will be blinded and assigned a unique clinical study specimen number. In order to preserve the confidentiality of subjects, the following procedures will be implemented at each site: * Clinical specimens will be individually numbered by an honest broker who is not involved in investigational testing so that the identity of the subject may not be readily ascertained by the investigator, investigational testing staff, or study Sponsor. * Available clinical information accompanying the specimens will be provided in such a way that it does not make the specimen source identifiable to the investigator or any other individuals associated with investigational testing, including the Sponsor. * No personal identifier (protected health information) will be included on the case report form (CRF) so that the confidentiality of each subject is protected. Multiple aliquots of each left-over specimen will be generated. One aliquot of each specimen will be shipped to a laboratory where the reference method (two validated real-time PCR methods for each, B. pertussis and B. parapertussis) will be performed. A second aliquot of each specimen will be used by the clinical sites for ARIES Bordetella Assay testing. Additional aliquots of each specimen will be stored frozen (-65 to -95°C) at the clinical sites and sent separately on dry ice to the Sponsor upon Sponsor's request. The prospective data set will be supplemented with banked, pre-selected clinical specimens and contrived specimens that tested positive by a comparator method for B. pertussis and B. parapertussis. If contrived specimens are required, these specimens will be prepared then blinded, aliquoted, randomized and frozen (-65 to -95°C) until distributed to the clinical testing sites by the Sponsor. The clinical data will be automatically generated from the ARIES System software. The system will report the specimen as B. pertussis and B. parapertussis positive (Co-infection), B. pertussis positive, B. parapertussis positive, B. pertussis and B. parapertussis negative or Invalid. Invalid results will be retested and both the original data and the retest data will be reported. The clinical data will be compared to the reference data and recorded in the clinical study reports.
Interventions
DEVICEARIES Bordetella Assay
Sponsors
Luminex Molecular Diagnostics
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Masking description
All eligible specimens (de-identified remnants) enrolled are tested using both the investigational device as well as the reference method.
Intervention model description
The study is comprised of three arms: Arm 1: Blinded, Prospective Arm Primary arm comprised of prospectively collected, de-identified, left-over nasopharyngeal swab specimens. Arm 2: Blinded, Pre-selected Arm Because both B. pertussis and B. parapertussis exhibited low prevalence rates in the prospective study cohort, the prospective sample set was supplemented with banked (pre-selected) positive specimens collected at selected sites. Arm 3: Contrived Specimens Because the number of B. parapertussis positive clinical specimens tested in Arm 1 and Arm 2 of the study was insufficient for accurate estimate of positive percent agreement (PPA) for this target, fifty (50) contrived specimens spiked with relevant B. parapertussis strains at different levels were also prepared. The analyte concentrations covered clinically relevant titers.
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. The specimen is a nasopharyngeal swab collected using a cleared nasopharyngeal swab and transport medium. 2. The specimen is from an adult or pediatric, male or female subject who is either hospitalized, admitted to a hospital emergency department, visiting an outpatient clinica or resident of a long term care facility. 3. The specimen is from a patient for whom a requisition has been made for B. pertussis and/or B. parapertussis testing. 4. The specimen is from a patient exhibiting clinical signs and symptoms of respiratory tract infection consistent with B. pertussis or B. parapertussis. 5. The specimen was received in good condition (no leakage or drying of the specimen). 6. The specimen contains a minimum volume of 1000 μL.
Exclusion criteria
1. The specimen is not a nasopharyngeal swab collected using a cleared nasopharyngeal swab and transport medium. 2. The specimen was not properly collected, transported, processed or stored according to the instructions provided by the Sponsor in Section 10 below. 3. The specimen volume is \<1000 μL. 4. Any specimen that was not tested per the complete testing algorithm provided by the Sponsor.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Specificity and sensitivity of the ARIES Bordetella Assay in patients suspected of having respiratory infection attributable to B. pertussis or B. parapertussis. | 5 months | Estimates of positive percent agreement and negative percent agreement for each target will be calculated based on a two-by-two table (reference method result vs. result from ARIES Bordetella Assay) for each target. In addition, 95% two sided confidence intervals will be provided. Positive agreement and negative agreement values will be provided for the entire prospective data set. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical performance of the ARIES Bordetella Assay per clinical site. | 5 months | Positive agreement and negative agreement values will be provided for each clinical site. |
| Clinical performance of the ARIES Bordetella Assay per age group. | 5 months | Positive agreement and negative agreement values will be provided for pediatric vs. adult patients. |
| Clinical performance of the ARIES Bordetella Assay per patient sub-population. | 5 months | Positive agreement and negative agreement values will be provided for each patient sub population (e.g., immuno-competent vs. immuno-compromised patients, and hospitalized vs. outpatient vs. long-term care facility). |
Countries
Canada, United States
Outcome results
None listed